Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

dacomitinib MeSH Supplementary Concept Data 2026


MeSH Supplementary
dacomitinib
Unique ID
C525726
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/C525726
Entry Term(s)
N-(4-(3-chloro-4-fluoroanilino)-7-methoxy-6-quinazolinyl)-4-(1-piperidinyl)-2-butenamide
PF 00299804
PF-00299804
PF00299804
Vizimpro
Pharm Action
Tyrosine Kinase Inhibitors
Registry Numbers
5092U85G58
Heading Mapped to
*Quinazolinones
Frequency
160
Note
a pan-ERBB inhibitor
Source
Cancer Res 2007 Dec 15;67(24):11924-32
Date Introduced
2008/01/14
Last Updated
2023/08/04
dacomitinib Preferred
PF 00299804 Related
N-(4-(3-chloro-4-fluoroanilino)-7-methoxy-6-quinazolinyl)-4-(1-piperidinyl)-2-butenamide Broader
Vizimpro Related
page delivered in 0.007s